<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03056222</url>
  </required_header>
  <id_info>
    <org_study_id>CF2 Rev.1 IMP</org_study_id>
    <nct_id>NCT03056222</nct_id>
  </id_info>
  <brief_title>CardioFocus vs. Contact Force Guided Pulmonary Vein Isolation in Paroxysmal Atrial Fibrillation</brief_title>
  <acronym>CF²</acronym>
  <official_title>CardioFocus vs. Contact Force Guided Pulmonary Vein Isolation in Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I-Med-Pro GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I-Med-Pro GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the acute procedure and safety outcomes as well as long
      term clinical outcomes of 2 groups of patients treated with the HeartLight® Endoscopically
      Guided Laser Ablation (EGLA) or a commercially available Contact Force Sensing Irrigated
      Radiofrequency (RF) Ablation Catheter plus, at the operator's discretion, 3D
      Electroanatomical Mapping (EAM) for the treatment of Paroxysmal Atrial Fibrillation (PAF).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 10, 2017</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from symptomatic, recurrent atrial fibrillation (AF) off of anti-arrhythmic drugs</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>Recurrent AF is defined as any documented episode of AF lasting more than 30 seconds after a blanking period of 90 days post procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute procedure success</measure>
    <time_frame>30 minutes post procedure</time_frame>
    <description>Confirmation of electrical isolation with a circular mapping catheter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure and fluoroscopy time</measure>
    <time_frame>During procedure</time_frame>
    <description>Time will be taken</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of peri-procedural complications</measure>
    <time_frame>From procedure to 12 months post procedure</time_frame>
    <description>E.g. major bleeding requiring intervention, phrenic nerve palsy, pericardial tamponade, thrombo-embolic events, pulmonary vein (PV) -stenosis, atrial-to-esophageal fistula, death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from symptomatic, recurrent Atrial Tachy Arrhythmia (ATA) off of anti-arrhythmic drugs</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>Recurrent ATA is defined as any documented episode of ATA lasting more than 30 seconds after a blanking period of 90 days post procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>HeartLight® EGLA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be treated with the endoscopically guided laser ablation catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Contact Force Sensing Irrigated RF ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be treated with a contact force sensing irrigated radiofrequency ablation catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ablation catheter</intervention_name>
    <description>Ablation of paroxysmal atrial fibrillation</description>
    <arm_group_label>Contact Force Sensing Irrigated RF ablation</arm_group_label>
    <arm_group_label>HeartLight® EGLA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must not have undergone a previous ablation for the treatment of PAF

          -  AF Type - Diagnosed with symptomatic paroxysmal atrial fibrillation (PAF) where PAF is
             defined as recurrent (two or more) episodes of AF that terminate spontaneously in less
             than seven days, usually less than 48 hours

        Exclusion Criteria:

          -  Atrial fibrillation secondary to a reversible cause or of non-cardiac origin

          -  Diagnosed with persistent atrial fibrillation defined as recurrent episodes lasting
             more than 7 and less than 365 days

          -  More than 4 electrical cardioversions in the year prior to enrollment but not
             including cardioversions performed within 48 hours of arrhythmia onset

          -  Documented left atrial thrombus on imaging

          -  Cannot be removed from anti-arrhythmic drugs for other reasons than atrial
             fibrillation

          -  New York Heart Association (NYHA) functional Class III or Class IV heart failure

          -  Left ventricular ejection fraction &lt; 30%

          -  Left atrial size &gt; 55 mm as measured in the parasternal antero-posterior view

          -  Myocardial infarction within 60 days prior to enrolment

          -  Woman of childbearing potential who is pregnant, lactating or not using adequate birth
             control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Metzner, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitäres Herz- und Gefäßzentrum UKE Hamburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hartcentrum OLV Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartcentrum Hasselt Jessa Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Homolce</name>
      <address>
        <city>Prague</city>
        <zip>15030</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isar Herz Zentrum</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vinzenz Hospital Köln</name>
      <address>
        <city>Köln</city>
        <state>NRW</state>
        <zip>50733</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKSH, Universitäres Herzzentrum</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Am Urban</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäres Herz- und Gefäßzentrum UKE Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blackpool Victoria Hospital</name>
      <address>
        <city>Blackpool</city>
        <zip>FY3 8NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 14, 2017</study_first_submitted>
  <study_first_submitted_qc>February 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2017</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

